A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells

Abstract

BackgroundTransferrin receptor (TfR) is a cell membrane-associated glycoprotein involved in the cellular uptake of iron and the regulation of cell growth. Recent studies have shown the elevated expression levels of TfR on cancer cells compared with normal cells. The elevated expression levels of this receptor in malignancies, which is the accessible extracellular protein, can be a fascinating target for the treatment of cancer. We have recently designed novel type of immunotoxin, termed "hybrid peptide", which is chemically synthesized and is composed of target-binding peptide and lytic peptide containing cationic-rich amino acids components that disintegrates the cell membrane for the cancer cell killing. The lytic peptide is newly designed to induce rapid killing of cancer cells due to conformational change. In this study, we designed TfR binding peptide connected with this novel lytic peptide and assessed the cytotoxic activity in vitro and in vivo.MethodsIn vitro: We assessed the cytotoxicity of TfR-lytic hybrid peptide for 12 cancer and 2 normal cell lines. The specificity for TfR is demonstrated by competitive assay using TfR antibody and siRNA. In addition, we performed analysis of confocal fluorescence microscopy and apoptosis assay by Annexin-V binding, caspase activity, and JC-1 staining to assess the change in mitochondria membrane potential. In vivo: TfR-lytic was administered intravenously in an athymic mice model with MDA-MB-231 cells. After three weeks tumor sections were histologically analyzed.ResultsThe TfR-lytic hybrid peptide showed cytotoxic activity in 12 cancer cell lines, with IC50 values as low as 4.0-9.3 μM. Normal cells were less sensitive to this molecule, with IC50 values > 50 μM. Competition assay using TfR antibody and knockdown of this receptor by siRNA confirmed the specificity of the TfR-lytic hybrid peptide. In addition, it was revealed that this molecule can disintegrate the cell membrane of T47D cancer cells just in 10 min, to effectively kill these cells and induce approximately 80% apoptotic cell death but not in normal cells. The intravenous administration of TfR-lytic peptide in the athymic mice model significantly inhibited tumor progression.ConclusionsTfR-lytic peptide might provide a potent and selective anticancer therapy for patients.

An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

“…TfR1 resides on cell membranes and imports cargo by receptormediated endocytosis via clathrin-coated pits. [ 4,8 ] Both SKBR3 and MDA-MB-231 cells possess high levels of TfR1 [ 33 ] which would assist cellular uptake of H-AFt-encapsulated-Gefi tinib. [ 34 ] The greater SKBR3 growth inhibition by H-AFt compared to MDA-MB-231 implies greater sequestration of H-AFt by SKBR3 cells.…”

Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents

“…It has previously been reported that agents that modulate iron metabolism in cancer cells, particularly those that restrict iron availability, including iron chelating agents (14,15) and transferrin receptor-targeted treatments (16), exhibit potent and broad anti-tumor activity. Several studies have demonstrated that the mechanism of the anti-tumor action of iron chelators is linked to the inhibition of DNA synthesis, the induction of DNA damage, G 1 -S phase cell cycle arrest, and the activation of apoptosis (15,17); however, research on targeting iron metabolism in cancer cells for anti-tumor therapy is still in its infancy (15).…”

HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor GrowthIn Vivo

“…Cell viability assay was done as described previously (15). Briefly, cells were seeded in 96-well plates at 3 Â 10 3 cells per well and incubated for 24 hours.…”